Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine-esketamine for Sleep Quality in ICU Patients
NCT05718024Phase 4Completed
- Sponsor
- Peking University First Hospital
- Start
- Nov 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine and esketamine in sleep disorders (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Percentage of non-rapid eye movement sleep stage 2 at 1 day. Started Nov 2023; status: completed.
02
Drugs
dexmedetomidineesketamine
03
Conditions
sleep disorders
Beyond the preview
Go deeper on NCT05718024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718024.